Pattern Bioscience
Pattern Bioscience is a privately held in vitro diagnostics company founded in 2016 and headquartered in Austin, Texas, developing a culture-free Single-Cell Microbiology system for rapid bacterial identification and antibiotic susceptibility testing (ID/AST). The platform isolates individual bacterial cells in picoliter-scale droplets and reads the metabolic patterns those cells produce over time, using machine learning to identify the pathogen and determine phenotypic susceptibility in hours instead of the days a culture workflow requires. The company holds FDA Breakthrough Device Designation for its Pneumonia Action Panel, raised $43M in Series D financing in November 2025 to pursue FDA clearance, and is backed by Illumina Ventures, Omnimed Capital, CARB-X, the AMR Action Fund and a $22.5M BARDA contract. Pattern is pre-commercial: it publishes a marketing and news site at pattern.bio and no public API, developer portal, SDK or machine-readable specification.
Pattern Bioscience is profiled on the APIs.io network. Tagged areas include Company, Diagnostics, Healthcare, Medical Devices, and In Vitro Diagnostics.
Pattern Bioscience’s developer surface includes engineering blog, product news, support, and 15 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Agent Surfaces 1
MCP servers, agent skills, and machine-readable catalogs
Access & Security 1
Authentication, authorization, and security posture
Operate 1
Status, limits, changes, and where to get help
Commercial 2
Pricing, plans, and the legal terms of use
Company 9
The organization behind the API
Scroll for all 9
Other 4
Properties that don't map to a standard resource type